Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide maintenance after first-line chemotherapy for high-intermediate/high-risk aggressive B-cell lymphoma
ChiCTR1900021789Phase 2Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of lenalidomide in aggressive B-cell lymphoma, diffuse large B-cell lymphoma (DLBCL) and large-cell lymphoma (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoint: Progression-free survival. Planned start Mar 2019; status: not yet recruiting.
02
Drugs
lenalidomide
03
Conditions
aggressive B-cell lymphomadiffuse large B-cell lymphoma (DLBCL)large-cell lymphoma
Beyond the preview
Go deeper on ChiCTR1900021789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900021789.